Truist analyst Joon Lee initiated coverage of Longboard Pharmaceuticals with a Buy rating and $60 price target. Lead drug bexicaserin, or bexi, is competitive to current market leader Fintepla in epilepsy and based on bexi’s superior safety and comparable efficacy to Fintepla, the firm thinks bexi could not only displace Fintepla but also further expand a market that remains under-penetrated at about 5%, the analyst tells investors. Bexi is due to start Phase 3 testing by year-end 2024, while Longboard’s second asset, LP659, is an S1P modulator with greater specificity to currently marketed S1P modulators whose Phase 1 data looks “promising with potential for greatest therapeutic window,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBPH:
- Longboard announces interim analysis results from OLE Phase 1b/2a PACIFIC study
- Truist healthcare analyst holds an analyst/industry conference call
- Longboard Pharmaceuticals price target raised to $45 from $36 at B. Riley
- Longboard Pharmaceuticals price target raised to $50 from $45 at Citi
- Longboard Pharmaceuticals Reports Promising LP659 Study Results